|drug1250||Face mask Wiki||1.00|
|drug361||BCG-10 vaccine Wiki||1.00|
|drug16||0.9% saline Wiki||0.58|
|D003141||Communicable Diseases NIH||0.07|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
The primary goal of our village-level intervention is to assess whether mask-wearing reduces community-level COVID-19 seroconversion. Our individual experiment assess whether masks protect against COVID-19 seroconversion. We also assess the efficacy of high-quality cloth vs. surgical masks.
Description: Symptomatic SARS-CoV2 infection, assessed via antibody testing 12 weeks after baseline, among individuals who report symptoms consistent with COVID-19 at 5 weeks or 9 weeks after baselineMeasure: Symptomatic SARS-CoV2 infection Time: 12 weeks
Description: Community experiment: Symptomatic SARS-CoV2 infection, assessed via antibody testing 12 weeks after baseline relative to baseline tests, among 25,000 high-risk individuals from randomly selected households Individual experiment: Symptomatic SARS-CoV2 infection, assessed via serological testing 10 weeks after baseline, among all 5,000 individuals in individual experimentMeasure: SARS-CoV2 infection Time: 12 weeks
Description: Wearing a mask of the nose, mouth, and chinMeasure: Observed prevalence of proper mask wearing Time: intervention weeks 0, 1, 2, 4, 6, 8, and 12 in the community experiment and intervention weeks 0, 1, 2, 4, and 6 in the individual experiment
Description: Prevalence of self-reported symptoms of COVID-19, including fever, cough, sore throat, shortness of breath, difficulty breathing, nasal congestion, and runny nose.Measure: Respiratory infection prevalence Time: 5 and 9 weeks
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports